Anodyne

Allergic conjunctivitis, Ocular inflammation, Miosis

Cataract Surgery 1 drop in affected eye(s) four times daily for 2 weeks, beginning 24 hours post-surgery Corneal Refractive Surgery 1-2 drop in affected eye(s) within 1 hour pre-op & 15 minutes post-op; continue 1-2 gtt four times daily for 3 days Inflammatory conditions Instill 1 drop in the conjunctival sac 4-5 times daily depending upon the severity of the diseases.

Safety & efficacy not established

Contraindicated to patients hypersensitive to Diclofenac Sodium or any other of its ingredients. Diclofenac sodium is also contraindicated in patients who may have NSAID induced asthma, urticaria, or acute rhinitis.

Inhibits cyclooxygenase (COX)-1 and COX-2, thereby inhibiting prostaglandin synthesis.May also inhibit neutrophil aggregation/activation, inhibit chemotaxis, decrease proinflammatory cytokine level, and alter lymphocyte activity.

Diclofenac eye drops may mask the signs of infection. So physicians should be alert to the development of infections in patients receiving the drug. During prolonged use, it is recommended that physicians conduct periodic examinations of the eye, including measurement of the intraocular pressure. Contact lenses should not be worn during treatment. Lactation: Excretion in milk significantly lower than systemic acministration of diclofenac; possibly compatible

Mild ocular stinging, irritation,May slow corneal wound healing,Lacrimation,Increased IOP,Keratitis,Dizziness,Insomnia,Pain,Fever,Chills,Nausea/vomiting,Abdominal pain,Corneal deposits,Corneal edema,Conjunctivitis,Irritation,Eyelid swelling,Corneal perforation,Corneal thinning

Pregnancy Category: C Lactation: Excretion in milk significantly lower than systemic acministration of diclofenac; possibly compatible

May increase serum levels of methotrexate. Concomitant use w/ other NSAIDs or anticoagulants (e.g. warfarin) is associated w/ higher risk of GI bleeding. Increased risk of nephrotoxicity w/ ciclosporin or triamterene. May increase the risk of developing corneal complications in patients w/ significant pre-existing corneal inflammation when use concomitantly w/ ophth preparation containing corticosteroids. Colestyramine and colestipol reduce the bioavailability of diclofenac. Decreased plasma concentration when administered after sucralfate. Ophth application of diclofenac may reduce the efficacy of ophth acetylcholine and carbachol. May increase serum levels of lithium and digoxin.